

Customer No. 31013

PATENT
116142-00170


AF 22W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pilon et al.

Serial No.: 09/898,616

Official Filing Date: July 2, 2001



For: METHOD FOR PRODUCTION OF PURIFIED RECOMBINANT
HUMAN UTEROGLOBIN FOR THE TREATMENT OF
INFLAMMATORY AND FIBROTIC CONDITIONS

Group Art Unit: 1647


Confirmation No.: 3118

Examiner: Lee, Betty

Mail Stop After Final
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop After Final, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 7, 2006.

Signature: 
Henry J. Cittiore

TERMINAL DISCLAIMER

Sir:

The owner, CC10 SWEDEN AB, of 100% interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of any patent granted on co-pending U.S. Patent Application Serial No. 10/187,498, filed July 2, 2002 (the "Co-pending Application"). The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the Co-pending Application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the Co-pending Application, as presently shortened by any terminal disclaimer, in the event that the Co-pending Application or any patent granted on the Co-pending Application is abandoned, does not issue, expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.


The Director is hereby authorized to charge the required fee of \$65.00 under 37 CFR 1.20(d) as well as any other fee(s) deemed necessary with the filing of this terminal disclaimer to Deposit Account No. 50-0540. A duplicate of this paper is enclosed.

The undersigned is an attorney of record and authorized to execute terminal disclaimers on behalf of CC10 SWEDEN AB.

Respectfully submitted,

KRAMER LEVIN NAFTALIS & FRANKEL LLP
Attorneys for Applicants
1177 Avenue of the Americas
New York, New York 10036

Dated: April 7, 2006



Barry Evans, Esq., Reg. No. 22,802
Henry J. Cittone, Esq., Reg. No. 57,206
(212) 715-9100 (telephone)
(212) 715-8000 (facsimile)